文献速递妇科肿瘤

WEE1抑制剂Adavosertib治疗复发性子宫浆液性癌的II期研究

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
PubMed 文献 · J Clin Oncol · 2021-03-11

这项单臂两阶段II期研究评估了Adavosertib单药治疗复发性子宫浆液性癌的疗效,共34例可评估患者,客观缓解率为29.4%(95%CI 15.1-47.5),6个月无进展生存率为47.1%(95%CI 29.8-64.9),中位无进展生存期6.1个月,中位缓解持续时间9.0个月,常见不良事件为腹泻、疲乏、恶心及血液学毒性。

要点

  • Adavosertib单药在复发性子宫浆液性癌中显示出持久的抗肿瘤活性。
  • 客观缓解率达29.4%,6个月无进展生存率为47.1%。
  • 常见不良事件包括腹泻、疲乏、恶心和血液学毒性。

核心结论

  • Adavosertib单药在复发性子宫浆液性癌女性中显示出令人鼓舞且持久的活性证据。
  • 建议进一步研究该药物及其活性生物标志物。

研究设计与样本

  • 单臂两阶段II期研究,共同主要终点为客观缓解率和6个月无进展生存率。
  • 34例可评估的复发性子宫浆液性癌患者接受Adavosertib单药治疗,起始剂量为300 mg口服,每日一次,第1-5天和第8-12天,21天为一周期,直至疾病进展。

主要发现

  • 在34例可评估患者中,共观察到10例缓解(1例确认的完全缓解,8例确认的部分缓解,1例未确认的部分缓解),客观缓解率为29.4%(95% CI 15.1-47.5)。
  • 中位无进展生存期为6.1个月,中位缓解持续时间为9.0个月。
  • 频繁的治疗相关不良事件包括腹泻(76.5%)、疲乏(64.7%)、恶心(61.8%)和血液学不良事件。
  • 探索性生物标志物分析未观察到临床活性与特定分子改变之间的明确相关性。

临床怎么用

  • Adavosertib单药可作为复发性子宫浆液性癌的一种有前景的治疗选择,但需进一步研究确认。

局限性

  • 单臂设计,样本量较小(34例可评估患者)。
  • 未发现临床活性与特定分子改变的明确相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Uterine serous carcinoma (USC) is a distinct histologic subtype of endometrial cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired with a high level of oncogene-driven replication stress. Adavosertib is a potent and selective oral inhibitor of the WEE1 kinase, a key regulator of the G2/M and S phase cell-cycle checkpoints. Because cells with impaired cell-cycle regulation and high replication stress may be vulnerable to WEE1 inhibition, we conducted this study to assess the activity of adavosertib monotherapy in women with recurrent USC. PATIENTS AND METHODS: This was a single-arm two-stage phase II study with coprimary end points of objective response rate (ORR) and rate of progression-free survival at 6 months (PFS6). Women with recurrent USC were treated with adavosertib monotherapy at a starting dose of 300 mg orally once daily days 1 through 5 and 8 through 12 of a 21-day cycle until disease progression. RESULTS: In 34 evaluable patients, 10 total responses (one confirmed complete response, eight confirmed partial responses, and one unconfirmed partial response) were observed with adavosertib monotherapy, for an ORR of 29.4% (95% CI, 15.1 to 47.5). Sixteen patients were progression-free at 6 months, for a PFS6 rate of 47.1% (95% CI, 29.8 to 64.9). Median PFS was 6.1 months, and median duration of response was 9.0 months. Frequent treatment-related adverse events (AEs) included diarrhea (76.5%), fatigue (64.7%), nausea (61.8%), and hematologic AEs. No clear correlation of clinical activity with specific molecular alterations was observed in an exploratory biomarker analysis. CONCLUSION: Adavosertib monotherapy demonstrated encouraging and durable evidence of activity in women with USC, and further investigation of this agent in this cancer and biomarkers of activity are indicated.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Liu JF, Xiong N, Campos SM, et al. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021. PMID: 33705205. doi:10.1200/JCO.20.03167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。